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ABSTRACT 
 
Background: Interaction between killer cell immunoglobulin-like receptors (KIR) and 
human leukocyte antigen (HLA) class I molecules is important for regulation of natural 
killer (NK) cell function. Objective: The aim of this study was to investigate the impact 
of compound KIR-HLA genotype on susceptibility to acute leukemia. Methods: 
Cohorts of Iranian patients with acute myeloid leukemia (AML; n=40) and acute 
lymphoid leukemia (ALL; n=38) were genotyped for seventeen KIR genes and their 
three major HLA class I ligand groups (C1, C2, Bw4) by a  combined polymerase chain 
reaction–sequence-specific primers (PCR-SSP) assay. The results were compared with 
those of 200 healthy control individuals. Results: We found a significantly decreased 
frequency of KIR2DS3 in AML patients compared to control group (12.5% vs. 38%, 
odds ratio=0.23, p=0.0018). Also, the KIR3DS1 was less common in AML group than 
controls (27.5% vs. 44.5%, p=0.0465, not significant after correction).  Other analyses 
including KIR genotypes, distribution and balance of inhibitory and activating 
KIR+HLA combinations, and co-inheritance of activating KIR genes with inhibitory 
KIR+HLA pairs were not significantly different between leukemia patients and the 
control group. However, in AML patients a trend toward less activating and more 
inhibitory KIR-HLA state was observed. Interestingly, this situation was not found in 
ALL patients and inhibition enhancement through increase of HLA ligands and inhibi-
tory combinations was the main feature in this group. Conclusion: Our findings may 
suggest a mechanism for escape of leukemic cells from NK cell immunity. 
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INTRODUCTION 
 
The Natural killer (NK) cells are a subset of lymphocytes comprising around 10% of 
total lymphocytes in peripheral blood (1). Due to their role in the innate response, NK 
cells provide the “first line of defense” against infectious agents and tumor cells (2-5). 
The ability of NK cells in spontaneously lysing tumor cells and their effective anti-
leukemic cytotoxic activity in vitro are suggestive of functions of these cells in “in 
vivo” anti-leukemia immune response (2,6,7). 
The activity of NK cells is regulated by several receptor systems. Killer cell immu-
noglobulin-like receptors (KIR) on NK cells and their ligands, i.e. Human Leucocyte 
Antigen (HLA) class I molecules, play a critical role in this tight regulation (8). The 
KIR2DL1 binds HLA-Cw2/4/5/6/15 allotypes (HLA-C2 group) that carry a lysine resi-
due at amino acid position 80. KIR2DL2 and 2DL3 recognize the remaining of the 
HLA-C allotypes (Cw1/3/7/8- HLA- C1 group) that carry an asparagine at the same po-
sition (9-12). KIR3DL1 binds to allotypes with Bw4 motif (HLA-Bw4), a serologically 
defined public epitope in α1 domain (residues 77-83) that presents on 40% of the HLA-
B allotypes (13-15) and certain HLA-A molecules (HLA-A23, A24, A25, and A32) 
(16,17). The dimorphic position 80 among the HLA-B Bw4-containing allotypes 
(Bw4Isoluecine80 and Bw4Threonine80) affects its interaction with KIR3DL1 subtypes, where 
HLA-B Bw4Ile80 generally exhibits stronger inhibition through KIR3DL1 compared to 
HLA-B Bw4Thr80 (18,19). The activating receptors KIR2DS1, 2DS2 and 3DS1 are 
thought to share HLA ligand binding specificities with their structurally related inhibi-
tory counterparts (KIR2DL1, 2DL2/3 and 3DL1, respectively) (20,21). The balance be-
tween the signals generated by these receptor-ligand pairs could lead to either triggering 
or blocking NK cell activity (22-24).   
To date, 15 KIR genes and 2 pseudogenes have been described. Eight genes encode for 
the inhibitory KIR (iKIR) receptors (2DL1-3, 3DL1-3, 2DL5A/B), six genes encode for 
the activating KIR (aKIR) receptors (2DS1-5, 3DS1), one gene encodes for KIR2DL4 
receptor with both inhibitory and activating functions, and two genes (2DP1 and 3DP1) 
are pseudogenes that do not encode a functional KIR receptor. Two basic KIR haplo-
types have been defined on the basis of gene content, and are termed haplotypes A and 
B. While the B haplotype has many activating genes, the A haplotype has one, and in 
many occasions, this gene (KIR2DS4) is present in a deleted form which is not believed 
to be expressed at the cell surface. Therefore, individuals with two A haplotypes (AA 
genotype) may not have any activating KIR gene (25,26). 
Several studies have shown lowered expression of HLA class I molecules in leukemia 
cells (27-29). Downregulation of HLA class I expression in leukemia cells relieves the 
inhibitory influence on NK cells, permitting NK cells to lyse these unhealthy target 
cells, a phenomenon first described as the ‘missing-self’ hypothesis (30). Furthermore, 
recent studies support a major role for NK cells in the graft-versus leukemia effect in 
allogeneic stem cell transplantation (31-33). Altogether, these data demonstrate that NK 
cells play a major role in the innate immune surveillance of leukemic cells (34).  
As KIR at chromosome 19q13.4 and HLA at chromosome 6p21.3 display extensive 
polymorphism, the independent segregation of these gene loci produce variations in the 
number and type of KIR+HLA pairs and aKIR genes inherited in individuals (35). Con-
sequently, the variable compound KIR-HLA ligand genotypes in a population may affect 
NK mediated innate immunity to control leukemia (34). In leukemia patients, failure in 
the clearance of leukemic cells could be caused by decreased activity of NK cells, 
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which may be the result of genetically determined KIR-HLA ligand gene content, lead-
ing to a dominance of inhibition over activation (36). This prompted us to investigate 
whether KIR and their known HLA ligand genes have predisposing roles in the occur-
rence of acute leukemia. In this study, we examined the protection/susceptibility to 
acute leukemia by analysing the frequencies and combinations of KIR and HLA ligand 
genes in patient groups and compared the results with a healthy control population. 
 
 
MATERIALS AND METHODS 
 
Patients and Controls. The patient groups consisted of 78 unrelated Iranian individuals 
with acute myeloid leukemia (AML; n=40; 25 males and 15 females; range 11-46 years) 
and acute lymphoid leukemia (ALL; n=38; 28 males and 10 females; range 13-33 
years). The institutional review board of the Bone Marrow Transplantation Center of 
Shariati Hospital (Tehran, Iran) approved the use of patient samples for this study. All 
samples were collected with the written consent of the patients or of their legal guardi-
ans. The control group consisted of 200 unrelated, healthy, Iranian individuals (100 
males and 100 females; range 20-50 years) whose KIR-HLA genotypes were character-
ized elsewhere (37). DNA samples were prepared from peripheral blood leukocytes by 
the salting-out method (38) and their quality and quantity were determined by ultravio-
let spectrophotometry. 
Combined KIR-HLA Ligand Genotyping. DNA samples were tested for the presence 
or absence of 17 KIR genes (2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS2, 
2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1 and 3DP1) and their three major 
HLA class I ligands (C1, C2 and Bw4), in a combined genotyping assay as previously 
described (37,39). In addition, non-deleted (*001) and deleted (*003/004/006/007/009) 
versions of KIR2DS4 gene were discriminated in all individuals. Only 2DS4*001 allele 
was considered as a functional activating gene in the analyses. Each individual KIR 
genotype was determined to be AA when only the activating gene KIR2DS4 was pre-
sent. Any individual with only the deleted version of KIR2DS4 was taken as having 
AA-zero (standing for zero aKIR gene) genotype. Other genotypes (AB or BB) which 
had additional activating genes besides 2DS4 were considered together as Bx (40).  
We grouped HLA-A, HLA-B and HLA-C alleles according to known ligand specificity 
for the following major inhibitory and activating KIR-HLA combinations: (i) 
KIR2DL2/L3 and KIR2DS2 with HLA-C1 alleles; (ii) KIR2DL1 and KIR2DS1 with 
HLA-C2 alleles; and (iii) KIR3DL1 and KIR3DS1 with HLA-B and HLA-A allotypes 
that contained the Bw4 epitope (HLA-Bw4 alleles). Moreover, we considered two sub-
groups (Bw4Ile80 and Bw4Thr80) in the analyses involving HLA-B Bw4 alleles. KIR3DL2 
pairing with HLA-A3/A11 private allotypes were not included in our study. We also de-
termined the presence of six aKIR genes in different iKIR+HLA pairs.  
Statistical Analysis. Carrier frequencies (CF) for KIR genes and HLA ligands were de-
termined by direct counting. Additionally, distribution in the patient and control groups 
for KIR genotypes (AA, AA-zero, and Bx), inhibitory and activating KIR+HLA pair-
ings, and genotype status regarding iKIR+HLA / aKIR+HLA and iKIR+HLA / aKIR (>, 
=, <) were defined. The significance of association was determined by χ2 test with 
Yate's correction and Fisher's exact test when relevant. All presented p values are uncor-
rected and labeling with ((*)) indicates values which remain significant (p<0.05) after 
correction. The odds ratio (OR) was calculated by the cross-product ratio. Exact confi-
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dence interval (CI) of 95% was obtained. For assessing the consistency of genotype dis-
tribution with Hardy-Weinberg equilibrium, χ2 test was used.  
 
 
RESULTS 
 
Frequencies of KIR Genes and Genotypes in the Controls and AML/ALL Patients. 
The distribution of carrier frequencies for KIR genes in AML patients, ALL patients and 
control group is presented in Table 1. The frequency of KIR genes was almost the same in 
all groups. Only the frequencies of KIR2DS3 and KIR3DS1 were less common in AML 
patients. The frequency of KIR2DS3 was significantly higher in controls than the AML 
group (38% vs. 12.5%, OR= 0.23, CI= 0.09-0.62, p=0.0018*). Also, KIR3DS1 was more 
frequent in control subjects compared to AML patients (44.5% vs. 27.5%, OR=0.47, 
CI=0.22-0.99, p=0.0465), although significance was lost after correction (Table 1). 
 
 
Table 1. Comparison of carrier frequencies of KIR genes, their HLA ligands, and 
KIR genotypes in the controls and AML/ALL patients. 
 
KIR Genes Con ols (n=200) tr
% F 
AML patients (n=40)  
% F 
ALL patients (n=38) 
% F 
Inhibitory 
2DL1 
  
  96.5 
   
  92.5 
   
  92.2 
2DL2/3 100 100 100 
2DL2   56.5   47.5   55.2 
2DL3   86.5   85.0   81.7 
2DL4 100 100 100 
2DL5   61.5   50.0   52.5 
2DL5A   40.0   45.0   39.5 
2DL5B   35.0   25.0   28.9 
3DL1   91.5   97.5   84.2 
3DL2 100 100 100 
3DL3 100 100 100 
Activating    
2DS1   45.5   42.5   44.6 
2DS2   57.5   52.5   55.2 
2DS3   38.0 12.5a   36.8 
2DS4   91.5   97.5   84.2 
2DS4-full   32.0   22.5   28.9 
2DS4-del   82.5   82.5   76.3 
2DS5   40.0   40.0   39.4 
3DS1   44.5   27.5b   39.4 
Pseudogene    
2DP1   96.5   97.5   92.2 
3DP1 100 100 100 
3DP1-full   30.5   25.0   21.1 
3DP1-del   97.0   97.5   94.7 
HLA ligands    
C1   76.0   80.0   73.6 
C2   72.0   67.5   86.9 
Bw4   76.5   80.0   84.2 
B Bw4Thr80   10.0   12.5     7.90 
B Bw4Ile80    56.5   70.0   68.4 
A Bw4   36.0   47.5   36.8 
KIR genotypes    
AA     8.5   10.0   13.2 
AA-zero   19.0   25.0   18.5 
Bx   72.5   65.0   68.3 
F: Frequency; a Corrected Significant differences; b Significant difference without correction. 
 
We identified a total of 19 different KIR genotypes (presence/absence of KIR genes) in 
leukemia patients vs. 26 genotypes in the control individuals (detailed genotype data is 
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not shown). The AA, AA-zero, and Bx (AB+BB) genotypes were counted in AML and 
ALL groups and compared to those obtained in the controls (Table 1). The AA-zero 
genotype was more frequent in AML patients than the control subjects (25% vs. 19%), 
whereas Bx genotypes had inverse distribution (65% vs. 72.5%). However, there was no 
significant difference in the frequency of KIR genotypes among study groups (Table 1).  
Frequencies of HLA Ligand Genes and Genotypes in the Controls and AML/ALL 
Patients. The carrier frequencies of HLA ligand genes in the AML patients, ALL pa-
tients and controls are illustrated in Table 1. In this study, HLA-B Bw4Ile80 was more 
common in subjects with AML compared to controls (70% vs. 56.5%, p=0.1134). In 
addition, HLA-C2 was found more frequently in ALL group compared to control sub-
jects (86.9% vs. 72%, p=0.0547). 
Six KIR ligand genotypes were identified in our study groups. The most common geno-
type, genotype 1 (presence of C1, C2, and Bw4), demonstrated an increased frequency 
in ALL patients compared to the controls (55.2% vs. 37.5%, p=0.0407). This difference 
failed to reach a significant level after correction (Table 2). 
 
 
Table 2. The frequencies of HLA ligand genotypes in the controls and AML/ALL 
patients. 
 
HLA ligands 
genotype # 
HLA-C1 
 
HLA-C2 
 
HLA-Bw4 
 
% of con-
trols (n=200) 
%  of  AML 
patients (n=40) 
%  of  ALL 
patients (n=38) 
1    37.5 40 55.2 a
2    23 22.5 10.5 
3    16 17.5 18.5 
4    10.5   7.5   5.3 
5      8   2.5   7.9 
6      5 10   2.6 
a Significant difference without correction. 
Note: Gray rectangles indicate presence and white rectangles indicate absence of HLA ligand genes. 
 
 
Relationship between KIR and HLA Ligand Genes in the Controls and AML/ALL 
Patients. Although 89% of the controls and 84.6% of the patients carried three iKIR 
genes (2DL1, 2DL2/3 and 3DL1), their ability to trigger inhibitory responses depends 
on the availability of the cognate HLA class I ligands. To determine the distribution of 
functional iKIR receptor, we established the frequency of the three iKIR+HLA pairs i.e. 
2DL1+HLA-C2, 2DL2/3+HLA-C1 and 3DL1+HLA-Bw4 in the control and patient 
groups (Table 3). The 2DL1+HLA-C2 was more common in ALL patients compared to 
control subjects (81.6% vs. 69.5%, p=0.1309). We also analyzed whether subgroups of 
Bw4 ligand are involved in the susceptibility to acute leukemia. The 3DL1+HLA-
Bw4Ile80 and 3DL1+HLA-A Bw4 genotypes were found to increase in the AML patients 
compared to control group (67.5% vs 52.5%, p=0.0817 and 45% vs 31%, p=0.0864, re-
spectively) ( Table 3). 
Furthermore, we hypothesized that the activating KIR genes might be more important in 
regulating the function of NK cells in acute leukemia. Thus, we explored the relation-
ship between the presence of activating KIR2DS1 in individuals expressing HLA-C2, 
KIR2DS2 in individuals expressing HLA-C1 and KIR3DS1 in individuals expressing 
HLA-Bw4. The KIR2DS2+HLA-C1 (35% vs. 44%, p=0.2948) and KIR3DS1+HLA-Bw4 
(20% vs. 33%, p=0.1041) were less common in subjects with AML compared to control 
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individuals. The other aKIR+HLA genotypes had nearly the same distribution in all 
groups (Table 3). 
 
Table 3. The frequencies of co-inheritance of inhibitory and activating KIR genes 
and their specific HLA class I ligands in the controls and AML/ALL patients. 
 
KIR+HLA combinations Controls (n=200) 
%  F 
AML patients (n=40)  
%  F 
ALL patients (n=38) 
%  F 
Inhibitory    
2DL2/3+C1 76.0 80.0 73.7 
2DL1+C2 69.5 62.5 81.6 
3DL1+Bw4 71.0 77.5 68.4 
3DL1+B Bw4 T   8.5 10.0   7.9 
3DL1+B Bw4 I 52.5 67.5 52.6 
3DL1+A Bw4 31.0 45.0 34.2 
Activating    
2DS2+C1 44.0 35.0 47.4 
2DS1+C2 31.0 30.0 34.2 
3DS1+Bw4 33.0 20.0 26.3 
3DS1+B Bw4 T   6.5   2.5   0.0 
3DS1+B Bw4 I 23.0 23.0 23.7 
3DS1+A Bw4 19.5 15.4   5.3 
F: Frequency 
 
The Number and Type of iKIR+HLA and aKIR+HLA Combinations in Controls 
and AML/ALL Patients. To determine the least number of iKIR receptor for cognate 
HLA class I molecule, we analysed the number and type of iKIR+HLA pairs inherited in 
the controls and patients. The frequency of 2DL2/3+C1 and 3DL1+Bw4 combinations 
(two inhibitory pairs) was lower in ALL patients compared to controls (10.5% vs. 
23.5%, p=0.0740) (Table 4). Whereas, ALL patients with all three inhibitory pairs were 
more frequent than the control group (39.5% vs. 31.5%, p=0.3371). Furthermore, the 
number and type of inherited aKIR+HLA pairs in the controls and patients were deter-
mined. Nearly the frequency of three, two, and one aKIR+HLA pair(s) were the same in 
all groups (Table 4). However, the frequency of none of the aKIR+HLA pair(s) was 
higher in AML patients than control individuals (45% vs. 35.5, p=0.2570). 
 
Table 4. Combination of inhibitory and activating KIR+HLA pairs and their  
frequencies in the controls and AML/ALL patients. 
 
Number of 
pairs 
KIR+HLA Controls (n=200) 
% F 
AML patients (n=40) 
% F 
ALL patients (n=38) 
% F 
Inhibitory     
Three 2DL2/3+C1, 2DL1+C2 and 3DL1+Bw4 31.5 35.0 39.5 
Two 2DL2/3+C1 and 2DL1+C2 14.5   7.5 15.8 
 2DL2/3+C1 and 3DL1+Bw4 23.5 27.5 10.5 
 2DL1+C2 and 3DL1+Bw4 15.5 15.0 18.4 
 2DL2/3+C1   6.5 10.0   7.9 
 2DL1+C2   8.0   5.0   7.9 
One 3DL1+Bw4   0.5     -     - 
Activating     
Three 2DS2+C1, 2DS1+C2 and 3DS1+Bw4 10.0   2.5 10.5 
Two 2DS2+C1 and 2DS1+C2   6.0 10.0   7.9 
 2DS2+C1 and 3DS1+Bw4   6.5   2.5   5.3 
 2DS1+C2 and 3DS1+Bw4 12.0 12.5   7.9 
One 2DS2+C1 21.5 20.0 23.7 
 2DS1+C2   3.0   5.0   7.9 
 3DS1+Bw4   5.5   2.5   2.6 
None - 35.5 45.0 34.2 
F: Frequency. 
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Relationship Between iKIR+HLA / aKIR+HLA and iKIR+HLA / aKIR Status in the 
Controls and AML/ALL Patients. To determine the correlation between the 
iKIR+HLA and aKIR+HLA pairs, we analyzed the combined frequencies of these com-
binations in the study groups (Table 5). In addition, the presence of six aKIR genes in 
the context of different iKIR+HLA pairs was also assessed (Table 5). The Analysis of 
combined frequencies for iKIR+HLA and aKIR+HLA pairs revealed that  the majority 
of controls and patients had iKIR+HLA>aKIR+HLA status. However, this kind of com-
pound genotype had higher frequency in AML patients than controls (75% vs. 69%, 
p=0.4523). Moreover, the frequency of genotypes with greater number of iKIR+HLA 
pair(s) than aKIR genes (iKIR+HLA>aKIR) was higher in subjects with AML compared 
to control individuals (45% vs. 35%, p=0.2314). No statistically significant dissimilarity 
in the frequency of different compound KIR-HLA genotypes between patients and con-
trols was found (Table 5). 
 
Table 5. The combined frequencies of different compound KIR-HLA genotypes 
in the controls and AML/ALL patients. 
 
KIR-HLA genotypes Con n=200) trols (
% F 
AML patients (n=40) 
% F 
ALL patients (n=38) 
% F 
iKIR+HLA>aKIR+HLA 69.0 75.0 63.2 
iKIR+HLA=aKIR+HLA 25.0 22.5 23.7 
iKIR+HLA<aKIR+HLA   6.0   2.5 13.1 
iKIR+HLA>aKIR 35.0 45.0 47.4 
iKIR+HLA=aKIR 20.0 20.0   5.2 
iKIR+HLA<aKIR 45.0 35.0 47.4 
F: Frequency 
 
 
DISCUSSION 
 
NK cells participate in the innate immunity against tumor or virus-infected cells with 
abnormal expression of HLA class I molecules. It has been proposed that the expression 
of HLA class I molecules is down regulated in leukemic cells (29, 41-43). Apparently, 
the NK cells of patients with leukemia are not able to destroy these leukemic cells and 
may let the malignant cells to escape from innate immune control. This failure may be 
due to the fact that NK cells are a fraction of the malignant clone and thus might have a 
decreased activity (41). Alternatively, these patients may show a compound KIR-HLA 
genotype unable to destroy leukemic cells (34).  
A previous study has reported a significant increase in KIR2DL2 and KIR2DS2 in Bel-
gium Caucasian patients of acute and chronic myeloid and lymphoid leukemia (34). Al-
though the numbers were small in some of the groups, this increase was obvious in all 
patients. A recent study has shown lowered frequencies, although not significant, of 
KIR2DL2 and KIR2DS2 in chronic myeloid leukemia (CML) patients and to a lesser 
extent in AML patients compared to controls (36). These results were in contrast to 
those of the present study. In this study, frequencies of KIR2DL2 and KIR2DS2 were the 
same in all groups. Conversely, the frequency of KIR2DS3 was significantly decreased 
in AML group (Table 1). In addition, an association (p=0.0465), not significant after 
correction, was observed for KIR3DS1 in AML patients compared to the controls. The 
reason for such opposing results remains to be investigated. 
In the study of Middleton et al. (36), when AA genotypes were analyzed to determine 
those with no activating KIR gene bar KIR2DL4 (AA-zero), 18.52% of AML and 25% 
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of CML patients had this AA genotype compared to 12.5% of the controls. Likewise, 
the frequency of AA-zero genotype was non-significantly higher in our subjects with 
AML compared to the controls (25% vs. 19%) (Table 1). On the other hand, Bx geno-
types were more common in the controls than in AML patients (72.5% vs. 65%). The 
above data may imply that the NK cells of a substantial number of AML patients are 
under an extra inhibitory condition caused by reduction of KIR B haplotypes and acti-
vating KIR genes. 
It has been confirmed that HLA genes are involved in enhancing genetic susceptibility 
of leukemia. In addition, function of KIR on effector cells is highly dependent on the 
HLA class I molecules expressed on targets. We have shown a non-significant increase 
of HLA-B Bw4Ile80 in the AML patients and a similar increase of HLA-C2 and HLA 
ligand genotype no. 1 in the ALL group (Table 1 and 2). The presence of more HLA 
ligands could possibly lead to greater inhibition of NK cell activity via inhibitory KIR 
ligation.  
As the regulation of NK cell response depends mainly on cognate recognition between 
products of KIR and HLA genes carried by an individual, it is proposed that the KIR-
HLA relationship may be important in a disease such as leukemia. In this regard, we lay 
particular emphasis on compound KIR-HLA genotype to determine its relative contribu-
tion to AML/ALL susceptibility. In a study performed by Verheyden et al., (44) an in-
creased frequency of KIR2DL2 and KIR2DS2 in combination with their ligand group 
(HLA-C1) has been reported in patients with myeloid leukemia (52.1% vs 31.7% in con-
trols). In our study, the increase of KIR3DL1+HLA-B Bw4Ile80 and KIR3DL1+HLA-A 
Bw4 in AML and KIR2DL1+HLA-C2 in ALL patients, although statistically not signifi-
cant, may be effective in the enhancement of inhibition. Furthermore, decreased fre-
quency of KIR2DS2+HLA-C1 and KIR3DS1+HLA-Bw4 in AML group may turn the 
NK balance to an added inhibitory situation (Table 3).  
NK cells, in contrast to T and B cells, employ a multiple receptor recognition strategy, 
whereby each NK cell can be triggered by various receptors separately or in combina-
tion, depending on the ligands presented by the target cell in a given encounter. If a pre-
sumed NK cell utilizes both inhibitory and activating receptors to recognize the target, 
the balance between these counter signals ensures the action of that NK cell. In this 
study, analysis of combined frequencies for iKIR+HLA against aKIR+HLA pairs re-
vealed that the majority of the study groups had iKIR+HLA>aKIR+HLA status, al-
though this kind of compound genotype had higher frequency in AML patients than 
controls (75% vs. 69%, p= 0.4523). On the other hand, the frequency of genotypes with 
greater number of iKIR+HLA pair(s) than aKIR genes (iKIR+HLA>aKIR) was higher in 
subjects with AML compared to the control individuals (45% vs. 35%, p=0.2314). Once 
again, these findings may represent a state of NK hyporesponsiveness through KIR-
HLA and aKIR pathways in these patients. 
In conclusion, the only significant difference found in the present study is related to the 
lower frequency of KIR2DS3 in AML patients than the control group. In addition, other 
non-significant differences in this patient group including decreased occurrence of 
KIR3DS1, deviated combined frequency of KIR+HLA combinations, and high rate of 
iKIR+HLA>aKIR+HLA and iKIR+HLA>aKIR compound genotypes had trends toward 
less activating and more inhibitory conditions. Interestingly, this situation was not ob-
served in ALL patients and the inhibition enhancement through increases of HLA 
ligands and inhibitory combinations was the main feature in this group.  It is noteworthy 
that in the use of HLA haplotype-mismatched donors, a significant graft vs. leukemia 
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effect was observed in AML but not in ALL patients (45). Moreover, a recent report has 
shown a significant improvement in graft survival at 3 years in AML patients in non-T-
cell-depleted unrelated donor stem cell transplantation when the donor had at least one 
B haplotype (i.e. presence of KIR2DL5, 2DS1, 2DS2, 2DS3, 2DS5, or 3DS1) (46). Thus, 
a genetic imbalance between activating and inhibitory KIR genes and KIR+HLA combi-
nations might have an influence on the susceptibility to acute leukemia by up-regulation 
of inhibition or by the loss of activation or a mixture of both, to favor the escape of ma-
lignant cells from NK cell immunity. Evaluating the role of other receptor-ligand pairs in-
volved in NK regulation may, however, better clarify further aspects of leukemia escape. 
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